What is the share price of Natco Pharma Ltd (NATCOPHARM) today?
The share price of NATCOPHARM as on 27th February 2026 is ₹988.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Natco Pharma Ltd (NATCOPHARM) share?
The past returns of Natco Pharma Ltd (NATCOPHARM) share are- Past 1 week: 11.97%
- Past 1 month: 19.33%
- Past 3 months: 11.98%
- Past 6 months: 13.99%
- Past 1 year: 24.07%
- Past 3 years: 82.11%
- Past 5 years: 20.44%
What are the peers or stocks similar to Natco Pharma Ltd (NATCOPHARM)?
The peers or stocks similar to Natco Pharma Ltd (NATCOPHARM) include:What is the dividend yield % of Natco Pharma Ltd (NATCOPHARM) share?
The current dividend yield of Natco Pharma Ltd (NATCOPHARM) is 0.61.What is the market cap of Natco Pharma Ltd (NATCOPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Natco Pharma Ltd (NATCOPHARM) is ₹17705.01 Cr as of 27th February 2026.What is the 52 week high and low of Natco Pharma Ltd (NATCOPHARM) share?
The 52-week high of Natco Pharma Ltd (NATCOPHARM) is ₹1059 and the 52-week low is ₹726.80.What is the PE and PB ratio of Natco Pharma Ltd (NATCOPHARM) stock?
The P/E (price-to-earnings) ratio of Natco Pharma Ltd (NATCOPHARM) is 9.39. The P/B (price-to-book) ratio is 2.33.Which sector does Natco Pharma Ltd (NATCOPHARM) belong to?
Natco Pharma Ltd (NATCOPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Natco Pharma Ltd (NATCOPHARM) shares?
You can directly buy Natco Pharma Ltd (NATCOPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Natco Pharma Ltd
NATCOPHARM Share Price
NSE₹988.501.68% (+16.35)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NATCOPHARM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NATCOPHARM Performance & Key Metrics
NATCOPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 11.37 | 2.33 | 0.61% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.86 | 5.82 | 0.58% |
36%
Analysts have suggested that investors can buy this stock
from 11 analysts
Price Upside
Earnings Growth
Rev. Growth
NATCOPHARM Company Profile
Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
SUNPHARMA
PE Ratio
38.13
38.13
1Y Return
5.43%
5.43%
Buy Reco %
94.29
94.29
TORNTPHARM
PE Ratio
76.73
76.73
1Y Return
45.07%
45.07%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
20.66
20.66
1Y Return
6.45%
6.45%
Buy Reco %
54.84
54.84
DRREDDY
PE Ratio
18.94
18.94
1Y Return
14.28%
14.28%
Buy Reco %
48.39
48.39
LUPIN
PE Ratio
32.06
32.06
1Y Return
21.73%
21.73%
Buy Reco %
72.22
72.22
NATCOPHARM Sentiment Analysis
NATCOPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
NATCOPHARM Stock Summary · February 2026
In Q3 FY26, the company demonstrated robust financial growth with consolidated revenues of INR 705.4 crores, driven by strong performance in emerging markets despite the absence of a key product. Management is strategically prioritizing mergers and acquisitions to achieve a long-term turnover goal of INR 10,000 crores, recognizing the limitations of organic growth in the generics market. Upcoming product launches, particularly in oncology and generics like semaglutide, are expected to enhance revenue, although regulatory challenges and a crowded market landscape present risks. The commitment to innovative R&D, including investments in CRISPR technology for organ transplantation, reflects a forward-looking approach to diversifying revenue streams and addressing market demands. Overall, the company is poised for significant growth while navigating operational complexities and competitive dynamics.
NATCOPHARM Stock Growth Drivers
NATCOPHARM Stock Growth Drivers
7Strong Financial Performance
The company reported a consolidated total revenue of INR 705.4 crores for the quarter ending
Successful Product Approvals and Launches
The company has made progress in obtaining approvals for generic versions of key products, including
NATCOPHARM Stock Challenges
NATCOPHARM Stock Challenges
2Decline in Revenue and Cost Management Challenges
The company is experiencing a decline in revenue, particularly due to anticipated decreases in sales
Patent Litigation and Uncertainty in Product Launches
There is significant uncertainty surrounding the patent filings and exclusivity for olaparib, with multiple patents
NATCOPHARM Forecast
NATCOPHARM Forecasts
Price
Revenue
Earnings
NATCOPHARM Share Price Forecast
NATCOPHARM Share Price Forecast
2026
Current
₹988.50
Baseline
Forecast for Feb 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹988.50
Baseline
Forecast for Feb 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
NATCOPHARM Company Revenue Forecast
NATCOPHARM Company Revenue Forecast
2025
Current
₹4.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹4.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
NATCOPHARM Stock EPS (Earnings Per Share) Forecast
NATCOPHARM Stock EPS (Earnings Per Share) Forecast
2025
Current
₹105.26
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹105.26
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
NATCOPHARM
NATCOPHARM
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NATCOPHARM Income Statement
NATCOPHARM Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,060.80 | 795.60 | 1,110.30 | 1,410.70 | 1,434.90 | 651.10 | 1,287.30 | 1,390.60 | 1,463.00 | 705.40 | ||||||||||
Operating & Other expenses | 573.40 | 490.50 | 571.00 | 557.80 | 566.80 | 436.00 | 672.90 | 757.90 | 783.80 | 488.60 | ||||||||||
EBITDA | 487.40 | 305.10 | 539.30 | 852.90 | 868.10 | 215.10 | 614.40 | 632.70 | 679.20 | 216.80 | ||||||||||
| Depreciation/Amortization | 43.60 | 44.20 | 55.50 | 44.10 | 45.80 | 47.00 | 98.30 | 57.60 | 52.40 | 46.20 | ||||||||||
| PBIT | 443.80 | 260.90 | 483.80 | 808.80 | 822.30 | 168.10 | 516.10 | 575.10 | 626.80 | 170.60 | ||||||||||
| Interest & Other Items | 4.20 | 4.60 | 6.20 | 5.20 | 4.10 | 4.40 | 10.20 | 3.20 | 13.10 | 9.50 | ||||||||||
| PBT | 439.60 | 256.30 | 477.60 | 803.60 | 818.20 | 163.70 | 505.90 | 571.90 | 613.70 | 161.10 | ||||||||||
| Taxes & Other Items | 70.60 | 43.60 | 91.30 | 135.10 | 140.90 | 30.70 | 99.30 | 91.20 | 95.30 | 9.60 | ||||||||||
| Net Income | 369.00 | 212.70 | 386.30 | 668.50 | 677.30 | 133.00 | 406.60 | 480.70 | 518.40 | 151.50 | ||||||||||
| EPS | 20.60 | 11.88 | 21.56 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 |
NATCOPHARM Company Updates
FY 2026FY 2026
Investor Presentation
Feb 12PDF
Aug 12PDF
Jul 23PDF
Jul 23PDF
NATCOPHARM Stock Peers
NATCOPHARM Past Performance & Peer Comparison
NATCOPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Natco Pharma Ltd | 9.39 | 2.33 | 0.61% |
| Sun Pharmaceutical Industries Ltd | 38.13 | 5.75 | 0.92% |
| Torrent Pharmaceuticals Ltd | 76.73 | 19.32 | 0.74% |
| Cipla Ltd | 20.66 | 3.48 | 1.19% |
NATCOPHARM Stock Price Comparison
Compare NATCOPHARM with any stock or ETFCompare NATCOPHARM with any stock or ETF
NATCOPHARM
NATCOPHARM Holdings
NATCOPHARM Shareholdings
NATCOPHARM Promoter Holdings Trend
NATCOPHARM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NATCOPHARM Institutional Holdings Trend
NATCOPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 1.07%
NATCOPHARM Shareholding Pattern
NATCOPHARM Shareholding Pattern
NATCOPHARM Shareholding History
NATCOPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in NATCOPHARM
Mutual Funds Invested in NATCOPHARM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Natco Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3961% | Percentage of the fund’s portfolio invested in the stock 0.78% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 38/43 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2898% | Percentage of the fund’s portfolio invested in the stock 1.54% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 34/73 (-8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2636% | Percentage of the fund’s portfolio invested in the stock 0.43% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/68 (-8) |
Compare 3-month MF holding change on Screener
smallcases containing NATCOPHARM stock
smallcases containing NATCOPHARM stock
Looks like this stock is not in any smallcase yet.
NATCOPHARM Events
NATCOPHARM Events
NATCOPHARM Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.62%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.17 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NATCOPHARM Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.62%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.17 every year
NATCOPHARM Upcoming Dividends
NATCOPHARM Upcoming Dividends
No upcoming dividends are available
NATCOPHARM Past Dividends
NATCOPHARM Past Dividends
Cash Dividend
Ex DateEx DateFeb 18, 2026
Interim 3
Interim 3 | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Feb 18, 2026
Cash Dividend
Ex DateEx DateNov 20, 2025
Interim 2
Interim 2 | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Nov 20, 2025
Cash Dividend
Ex DateEx DateAug 19, 2025
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 19, 2025
Cash Dividend
Ex DateEx DateFeb 18, 2025
Interim 3
Interim 3 | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Feb 18, 2025
Cash Dividend
Ex DateEx DateNov 27, 2024
Interim 2
Interim 2 | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Nov 27, 2024
NATCOPHARM Stock News & Opinions
NATCOPHARM Stock News & Opinions
Articles & Videos
Spotlight
Volumes jump at Natco Pharma Ltd counter
Akums Drugs & Pharmaceuticals Ltd, RHI Magnesita India Ltd, Brainbees Solutions Ltd, Inox Wind Ltd are among the other stocks to see a surge in volumes on NSE today, 16 February 2026.Natco Pharma Ltd witnessed volume of 188.67 lakh shares by 14:14 IST on NSE, a 30.19 times surge over two-week average daily volume of 6.25 lakh shares. The stock increased 9.68% to Rs.903.60. Volumes stood at 4.52 lakh shares in the last session.Akums Drugs & Pharmaceuticals Ltd registered volume of 22.18 lakh shares by 14:14 IST on NSE, a 21.84 fold spurt over two-week average daily volume of 1.02 lakh shares. The stock rose 6.35% to Rs.480.00. Volumes stood at 70716 shares in the last session.RHI Magnesita India Ltd registered volume of 13.51 lakh shares by 14:14 IST on NSE, a 9.47 fold spurt over two-week average daily volume of 1.43 lakh shares. The stock rose 4.88% to Rs.457.95. Volumes stood at 1.13 lakh shares in the last session.Brainbees Solutions Ltd clocked volume of 77.54 lakh shares by 14:14 IST on NSE, a 7.68 times surge over two-week average daily volume of 10.10 lakh shares. The stock lost 10.49% to Rs.241.50. Volumes stood at 10.2 lakh shares in the last session.Inox Wind Ltd notched up volume of 456.78 lakh shares by 14:14 IST on NSE, a 6.18 fold spurt over two-week average daily volume of 73.91 lakh shares. The stock slipped 3.03% to Rs.103.16. Volumes stood at 78.58 lakh shares in the last session.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Natco Pharma receives CDSCO approval for launch of Semaglutide in India
Natco Pharma received approval for Semaglutide from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March'26. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Natco Pharma receives USFDA EIR report for API unit in Chennai
NATCO Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical Ingredient Division located in Manali, Chennai from 17 November ' 21 November 2025. The Company received seven (7) observation in the Form-483. Further, the Company has received the EIR (Establishment Inspection Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI). Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Natco Pharma recommends interim dividend
Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 February 2026, inter alia, have recommended the interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Natco Pharma consolidated net profit rises 13.91% in the December 2025 quarter
Net profit of Natco Pharma rose 13.91% to Rs 151.50 crore in the quarter ended December 2025 as against Rs 133.00 crore during the previous quarter ended December 2024. Sales rose 36.33% to Rs 647.30 crore in the quarter ended December 2025 as against Rs 474.80 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales647.30474.80 36 OPM %24.528.17 - PBDT207.30210.70 -2 PBT161.10163.70 -2 NP151.50133.00 14 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
NATCO Pharma receives USFDA tentative approval for Erdafitinib tablets
NATCO Pharma received tentative approval from the USFDA for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa' by Janssen Biotech Inc. NATCO's Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy. Erdafitinib tablets had estimated sales of approximately USD 60 million in the U.S. for 12 months ending Sep'25 as per industry sales data.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
NATCO Pharma Asia acquires 49% stake in PT NATCO Lotus Farma
NATCO Pharma Asia, a wholly-owned subsidiary (WOS) of Natco Pharma (NATCO) incorporated in Singapore, has acquired 49% of shareholding in PT NATCO Lotus Farma from PT Lotus Farma Indonesia. NATCO already owns 51% of PT NATCO Lotus Farma. Post this acquisition, NATCO along with its WOS wholly-owns 100% of PT NATCO Lotus Farma.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Natco Pharma to hold board meeting
Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Natco Pharma announces change in senior management
Natco Pharma has appointed Amit Parekh as Executive Vice President - Finance and Accounts of the Company with effect from 2nd December 2025 and as part of the Company's structured succession planning; subject to necessary approvals; Amit Parekh will succeed S.V.V.N. Appa Rao, Chief Financial Officer of the Company at the Board meeting to be held in the month of February 2026. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Natco Pharma receives affirmation in credit ratings from ICRA
Natco Pharma announced that ICRA has reaffirmed/ assigned the rating ICRA AA; Stable/ ICRA A1+ for various debt facilities of the company. Powered by Capital Market - Live
2 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 18.79%, vs industry avg of 9.88%
Over the last 5 years, market share increased from 0.79% to 1.13%
Over the last 5 years, net income has grown at a yearly rate of 32.55%, vs industry avg of 19.69%